Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study

Sarah A. Taylor, Cathryn Rankin, Jeannette J. Townsend, Johnny B. Craig, Ralph B. Vance, Dilip L. Solank, Thomas D. Brown, Kurt Jaeckle

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Amonafide 300 mg/M 2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.

Original languageEnglish (US)
Pages (from-to)113-115
Number of pages3
JournalInvestigational New Drugs
Volume20
Issue number1
DOIs
StatePublished - Apr 6 2002

Fingerprint

amonafide
Central Nervous System Neoplasms
Nervous System
Appointments and Schedules
Central Nervous System
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Taylor, S. A., Rankin, C., Townsend, J. J., Craig, J. B., Vance, R. B., Solank, D. L., ... Jaeckle, K. (2002). Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study. Investigational New Drugs, 20(1), 113-115. https://doi.org/10.1023/A:1014488922368
Taylor, Sarah A. ; Rankin, Cathryn ; Townsend, Jeannette J. ; Craig, Johnny B. ; Vance, Ralph B. ; Solank, Dilip L. ; Brown, Thomas D. ; Jaeckle, Kurt. / Phase II trial of amonafide in central nervous system tumors : A Southwest Oncology Group Study. In: Investigational New Drugs. 2002 ; Vol. 20, No. 1. pp. 113-115.
@article{163381bb0a014755b3cddfc8eacea5fd,
title = "Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study",
abstract = "Amonafide 300 mg/M 2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.",
author = "Taylor, {Sarah A.} and Cathryn Rankin and Townsend, {Jeannette J.} and Craig, {Johnny B.} and Vance, {Ralph B.} and Solank, {Dilip L.} and Brown, {Thomas D.} and Kurt Jaeckle",
year = "2002",
month = "4",
day = "6",
doi = "10.1023/A:1014488922368",
language = "English (US)",
volume = "20",
pages = "113--115",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

Taylor, SA, Rankin, C, Townsend, JJ, Craig, JB, Vance, RB, Solank, DL, Brown, TD & Jaeckle, K 2002, 'Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study', Investigational New Drugs, vol. 20, no. 1, pp. 113-115. https://doi.org/10.1023/A:1014488922368

Phase II trial of amonafide in central nervous system tumors : A Southwest Oncology Group Study. / Taylor, Sarah A.; Rankin, Cathryn; Townsend, Jeannette J.; Craig, Johnny B.; Vance, Ralph B.; Solank, Dilip L.; Brown, Thomas D.; Jaeckle, Kurt.

In: Investigational New Drugs, Vol. 20, No. 1, 06.04.2002, p. 113-115.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of amonafide in central nervous system tumors

T2 - A Southwest Oncology Group Study

AU - Taylor, Sarah A.

AU - Rankin, Cathryn

AU - Townsend, Jeannette J.

AU - Craig, Johnny B.

AU - Vance, Ralph B.

AU - Solank, Dilip L.

AU - Brown, Thomas D.

AU - Jaeckle, Kurt

PY - 2002/4/6

Y1 - 2002/4/6

N2 - Amonafide 300 mg/M 2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.

AB - Amonafide 300 mg/M 2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.

UR - http://www.scopus.com/inward/record.url?scp=0036204930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036204930&partnerID=8YFLogxK

U2 - 10.1023/A:1014488922368

DO - 10.1023/A:1014488922368

M3 - Article

C2 - 12003186

AN - SCOPUS:0036204930

VL - 20

SP - 113

EP - 115

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -